DE69331319T2 - Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren - Google Patents

Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren

Info

Publication number
DE69331319T2
DE69331319T2 DE69331319T DE69331319T DE69331319T2 DE 69331319 T2 DE69331319 T2 DE 69331319T2 DE 69331319 T DE69331319 T DE 69331319T DE 69331319 T DE69331319 T DE 69331319T DE 69331319 T2 DE69331319 T2 DE 69331319T2
Authority
DE
Germany
Prior art keywords
biotin
methods
pretargeting
processes
dota conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331319T
Other languages
English (en)
Other versions
DE69331319D1 (de
Inventor
J Theodore
M Gustavson
M Reno
B Axworthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/895,588 external-priority patent/US5283342A/en
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69331319D1 publication Critical patent/DE69331319D1/de
Publication of DE69331319T2 publication Critical patent/DE69331319T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
DE69331319T 1992-06-09 1993-06-07 Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren Expired - Fee Related DE69331319T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/895,588 US5283342A (en) 1992-06-09 1992-06-09 Biotinylated small molecules
US99538392A 1992-12-23 1992-12-23
US99538192A 1992-12-23 1992-12-23
PCT/US1993/005406 WO1993025240A2 (en) 1992-06-09 1993-06-07 Pretargeting methods and compounds

Publications (2)

Publication Number Publication Date
DE69331319D1 DE69331319D1 (de) 2002-01-24
DE69331319T2 true DE69331319T2 (de) 2002-08-08

Family

ID=27420561

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331319T Expired - Fee Related DE69331319T2 (de) 1992-06-09 1993-06-07 Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren

Country Status (7)

Country Link
US (2) US5608060A (de)
EP (2) EP0646019B9 (de)
JP (1) JPH07507804A (de)
AT (1) ATE210464T1 (de)
CA (1) CA2134239C (de)
DE (1) DE69331319T2 (de)
WO (1) WO1993025240A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US6358490B2 (en) * 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
IL108388A0 (en) * 1993-01-21 1994-04-12 Harvard College Amplified direction of effector groups to specific target cells in an animal
WO1994017829A1 (en) * 1993-02-02 1994-08-18 Neorx Corporation Directed biodistribution of small molecules
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
KR100220864B1 (ko) * 1993-05-17 1999-09-15 오트리브 데이비스 더블유 비오틴/아비딘-금속 단백질 콘쥬게이트로 병변을 검출 및 치료하기 위한 조성물
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
CA2165538A1 (en) * 1993-08-17 1995-02-23 Sudhakar Kasina S3n chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
EP0733066B1 (de) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting verfahren und mitteln
WO1995015978A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
DE69533105T2 (de) * 1994-06-06 2005-06-09 The Jmde Trust, Newton Biotinverbindungen zum zielen auf tumore und infektionsherde
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
JPH0889278A (ja) * 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US6155266A (en) * 1995-05-08 2000-12-05 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
US5846537A (en) * 1995-06-07 1998-12-08 University Of Rochester Modified avidin and streptavidin and methods of use thereof
DE69638134D1 (de) * 1995-06-07 2010-04-08 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
JP2000503301A (ja) * 1996-01-11 2000-03-21 テクニクローン インコーポレーティッド 減少した正味の正電荷を有する抗体
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
WO1997046099A1 (en) * 1996-06-06 1997-12-11 Neorx Corporation Liver retention clearing agents
EP0937090B1 (de) * 1996-10-08 2002-08-07 Kreatech Biotechnology B.V. Verfahren zur markierung von nukleotiden, markierte nukleotide und nuetzliche zwischenprodukte
AU6701498A (en) * 1997-03-14 1998-09-29 Trustees Of Boston University Multiflavor streptavidin
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
CN1217698C (zh) * 1998-08-24 2005-09-07 马克西姆药品公司 应用h2受体激动剂和其它t细胞活化剂激活和保护t细胞(cd4+和cd8+)
IL131266A0 (en) 1999-08-05 2001-01-28 N S T Neurosurvival Technologi Peptides and pharmaceutical compositions comprising same
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
US6365379B1 (en) * 1998-10-06 2002-04-02 Isis Pharmaceuticals, Inc. Zinc finger peptide cleavage of nucleic acids
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
AU2610000A (en) 1999-01-12 2000-08-01 Cambridge University Technical Services Limited Compounds and methods to inhibit or augment an inflammatory response
US6454789B1 (en) * 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
CA2356532A1 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
WO2000071171A2 (en) * 1999-05-21 2000-11-30 Wake Forest University Sigma-1 ligands for determining carcinoma proliferative status
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1190061A1 (de) * 1999-06-07 2002-03-27 Neorx Corporation Streptavidin exprimierte genfusion und methoden zu deren verwendung
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001028595A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
KR20020059618A (ko) * 1999-10-15 2002-07-13 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 이미지화제 및 항종양제로서 유용한 코발라민 콘쥬게이트
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
DE19956029A1 (de) * 1999-11-22 2001-05-23 Aventis Pharma Gmbh Trägersysteme enthaltend Hüllsubstanzen mit enzymatisch abspaltbaren Seitengruppen
US20020049247A1 (en) 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
PL212211B1 (pl) * 2000-06-02 2012-08-31 Regents Board Of Kompozycja do wytwarzania scyntygraficznego środka obrazującego, kompozycja do obrazowania scyntograficznego, sposób syntezy znakowanego radionuklidem koniugatu etylenodicysteiny z ligandem naprowadzającym do obrazowania, zastosowanie kompozycji zawierającej znakowany radionklidem konigat etylenodiscysteiny z ligandem naprowadzającym do wytwarzania środków farmaceutycznych do obrazowania nowotworu albo miejsca infekcji oraz zestaw do wytwarzania preparatów radiofarmaceutycznych
AU2001288829A1 (en) * 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
TWI228512B (en) * 2000-10-25 2005-03-01 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1390081A2 (de) * 2001-01-08 2004-02-25 Neorx Corporation Therapeutische und diagnostische verbindungen, zusammenstellungen und methoden
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US6962903B2 (en) * 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003000010A2 (en) * 2001-06-20 2003-01-03 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
US20030144198A1 (en) * 2001-09-28 2003-07-31 Collins Douglas A. Coadministration of transport protein with conjugated cobalamin to deliver agents
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".
CN100579577C (zh) 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
KR100440725B1 (ko) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
KR20050062605A (ko) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) 종양 특이적 에피토프에 대해 지정된 표지된 활성화임파구를 이용한 종양의 검출, 위치결정 및 병기결정
ATE517638T1 (de) * 2003-01-31 2011-08-15 Immunomedics Inc Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US8293522B2 (en) * 2004-05-13 2012-10-23 Centre National De La Recherche Scientifique Device for binding a target entity to a bait entity and detection methods using the same
US20050271585A1 (en) * 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US20080181847A1 (en) * 2004-10-07 2008-07-31 Koninklijke Philips Electronics, N.V. Targeted Imaging and/or Therapy Using the Staudinger Ligation
EP1893038A1 (de) * 2005-05-17 2008-03-05 Cargill, Incorporated Granulatförmige lecithine, granulatförmige lysolecithine, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen
TWI381852B (zh) * 2005-09-27 2013-01-11 Sigma Tau Ind Farmaceuti 生物素二胺基衍生物類及其與大環螯合劑之共軛物
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
NO2399993T3 (de) 2009-02-20 2018-02-17
FI20090100A0 (fi) 2009-03-16 2009-03-16 Wallac Oy Biotinidaasimääritys
GB0922369D0 (en) 2009-12-22 2010-02-03 Hammersmith Imanet Ltd Labelled biotin conjugates
JP6155193B2 (ja) 2010-11-18 2017-06-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ ヒト免疫不全ウイルスに対する抗体動員及び進入阻害活性を有する二官能性分子
GB201205360D0 (en) 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
JP6178586B2 (ja) 2013-02-20 2017-08-09 サヴィッド・セラピューティックス株式会社 ビオチン改変体、ストレプトアビジン変異体およびそれらの利用
EP3068443B1 (de) 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualisierungsvernetzer und verwendungen davon
EP3109252B1 (de) 2014-02-18 2020-12-30 Savid Therapeutics Inc. Modifiziertes biotin, streptavidin mutante, und verwendung davon
EP3316871A4 (de) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York Talkgebundene zusammensetzung und verwendungen davon
EP3546470A4 (de) 2016-11-25 2020-08-05 Savid Therapeutics Inc. Klärmittel
CN110891614A (zh) 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
AU2018261888B2 (en) 2017-05-05 2022-06-30 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2019230905A1 (ja) 2018-05-30 2019-12-05 国立大学法人 東京大学 ハロゲン化したビオチン改変二量体およびその利用
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
JPWO2020032165A1 (ja) 2018-08-08 2021-08-12 国立大学法人 東京大学 ビオチン改変二量体とフタロシアニン染料とのコンジュゲート
JP2023511756A (ja) 2020-01-31 2023-03-22 アヴィラー セラピューティクス インコーポレイテッド 細胞外タンパク質を分解するａｓｇｐｒ結合性化合物
JPWO2021210573A1 (de) 2020-04-14 2021-10-21
EP4141017A1 (de) 2020-04-24 2023-03-01 The University of Tokyo Duocarmycinderivat und verwendung davon

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
NZ211453A (en) * 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
ATE81341T1 (de) * 1986-07-03 1992-10-15 Upjohn Co Verfahren zur herstellung von antibiotica 10381b.
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3722647A1 (de) * 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
EP0327365B1 (de) * 1988-02-03 1994-06-15 Hybritech Incorporated Modifizierte Haptene, nützlich als bildformendes Agens und als Arzneimittel
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US4895955A (en) * 1988-05-27 1990-01-23 Lifecodes Corporation Non-radioactive carbodiimide precursor to nucleic acid probes
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
SE465155B (sv) * 1989-12-19 1991-08-05 Exploaterings Ab Tbf Metallkelatbildande hydrofil polymer foer adsorption etc samt ett saett foer framstaellning av polymeren
WO1991009628A1 (de) * 1989-12-27 1991-07-11 Boehringer Ingelheim International Gmbh Verwendung eines antikoagulant als diagnostikum
JP2776953B2 (ja) * 1990-04-10 1998-07-16 日本メジフィジックス株式会社 多官能性金属キレート化合物とその用途
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
WO1994017829A1 (en) * 1993-02-02 1994-08-18 Neorx Corporation Directed biodistribution of small molecules

Also Published As

Publication number Publication date
EP1138334A2 (de) 2001-10-04
ATE210464T1 (de) 2001-12-15
EP1138334A3 (de) 2002-04-03
DE69331319D1 (de) 2002-01-24
EP0646019B9 (de) 2002-12-18
US5630996A (en) 1997-05-20
WO1993025240A3 (en) 1994-02-17
JPH07507804A (ja) 1995-08-31
US5608060A (en) 1997-03-04
EP0646019B1 (de) 2001-12-12
CA2134239C (en) 2004-11-23
EP0646019A1 (de) 1995-04-05
WO1993025240A2 (en) 1993-12-23
CA2134239A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
DE69331319D1 (de) Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
DK0775142T3 (da) Substituerede O6-benzylguaniner
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
FI882390A0 (fi) Tetratsolit, jotka ovat verenpainetta alentavien yhdisteiden välituotteita
EP0896533A4 (de) Pentafluorobenzensulfonamiden und analoge
IL162152A0 (en) Tissue inhibitor metalloproteinase type three (timp-3) composition and methods
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
FI973048A0 (fi) Menetelmät ja koostumukset hydrofiilisten molekyylien lipidisoimiseksi
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
ES2181501T3 (es) Composicion cosmetica.
DE3028340C2 (de)
GB9621437D0 (en) Improvements in or relating to organic compositions
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
ATE247955T1 (de) Selenophen-antitumormittel
ATE118012T1 (de) 2'-deoxy-2'-methylidenecytidin-dihydrat, verfahren zu ihrer herstellung und mischmaterial.
TR199901165A2 (xx) Piretroid bile�imi ve salg�n hastal�klar� i�in bunu i�eren bile�ikler.
IT8921095A0 (it) Composizione per l'aumento del guadagno di peso.
ATE119779T1 (de) Verwendung von 5'-vinylhalo- aristeromycin/adenosin-analoga als immunsuppressiva.
BE903651A (fr) Alpha - (((2 - hydroxy -1,1- dimethyl - ethyl) amino) methyl), benzene methanol et ses sels, leurs procedes de preparation et leur utilisation.
ITCH920006A0 (it) Strumento dell'autovettura per pagamento parcheggio.
IT235779Y1 (it) Struttura ausiliaria per macchine rullatrici tipo "roto-flo"

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee